These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 39329452)

  • 1. SNRPB2 promotes triple-negative breast cancer progression by controlling alternative splicing of MDM4 pre-mRNA.
    Yu S; Si Y; Yu J; Jiang C; Cheng F; Xu M; Fan Z; Liu F; Liu C; Wang Y; Wang N; Liu C; Bi C; Sun H
    Cancer Sci; 2024 Sep; ():. PubMed ID: 39329452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MCPIP1-mediated NFIC alternative splicing inhibits proliferation of triple-negative breast cancer via cyclin D1-Rb-E2F1 axis.
    Chen F; Wang Q; Yu X; Yang N; Wang Y; Zeng Y; Zheng Z; Zhou F; Zhou Y
    Cell Death Dis; 2021 Apr; 12(4):370. PubMed ID: 33824311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Insights Into Triple-Negative Breast Cancer Prognosis by Comprehensive Characterization of Aberrant Alternative Splicing.
    Gong S; Song Z; Spezia-Lindner D; Meng F; Ruan T; Ying G; Lai C; Wu Q; Liang Y
    Front Genet; 2020; 11():534. PubMed ID: 32595697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ZMIZ2 promotes the development of triple-receptor negative breast cancer.
    Zou X; Liu Y; Di J; Wei W; Watanabe N; Li J; Li X
    Cancer Cell Int; 2022 Jan; 22(1):52. PubMed ID: 35101047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PRPF19 regulates p53-dependent cellular senescence by modulating alternative splicing of MDM4 mRNA.
    Yano K; Takahashi RU; Shiotani B; Abe J; Shidooka T; Sudo Y; Yamamoto Y; Kan S; Sakagami H; Tahara H
    J Biol Chem; 2021 Jul; 297(1):100882. PubMed ID: 34144037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The oncogenic kinase NEK2 regulates an RBFOX2-dependent pro-mesenchymal splicing program in triple-negative breast cancer cells.
    Naro C; De Musso M; Delle Monache F; Panzeri V; de la Grange P; Sette C
    J Exp Clin Cancer Res; 2021 Dec; 40(1):397. PubMed ID: 34930366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA-binding protein MSI2 isoforms expression and regulation in progression of triple-negative breast cancer.
    Li M; Li AQ; Zhou SL; Lv H; Wei P; Yang WT
    J Exp Clin Cancer Res; 2020 May; 39(1):92. PubMed ID: 32448269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
    Li M; Li A; Zhou S; Lv H; Yang W
    J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The circRNA circSEPT9 mediated by E2F1 and EIF4A3 facilitates the carcinogenesis and development of triple-negative breast cancer.
    Zheng X; Huang M; Xing L; Yang R; Wang X; Jiang R; Zhang L; Chen J
    Mol Cancer; 2020 Apr; 19(1):73. PubMed ID: 32264877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NAA20 recruits Rin2 and promotes triple-negative breast cancer progression by regulating Rab5A-mediated activation of EGFR signaling.
    Qiao L; Dong C; Jia W; Ma B
    Cell Signal; 2023 Dec; 112():110922. PubMed ID: 37827343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SNRPB2 in the pan-cancer landscape: A bioinformatics exploration and validation in hepatocellular carcinoma.
    Li B; Liu J; Huang L; Cai J; Guo L; Xu L; Xu Q; Liu J; Huang J; Hu W; Tang X; Liu Z; Liu T
    Cell Signal; 2024 Dec; 124():111445. PubMed ID: 39366532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNPS1 functions as an oncogenic splicing factor in cervical cancer cells.
    Deka B; Chandra P; Yadav P; Rehman A; Kumari S; Kunnumakkara AB; Singh KK
    IUBMB Life; 2023 Jun; 75(6):514-529. PubMed ID: 36300671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
    Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
    Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long noncoding RNA Linc00339 promotes triple-negative breast cancer progression through miR-377-3p/HOXC6 signaling pathway.
    Wang X; Chen T; Zhang Y; Zhang N; Li C; Li Y; Liu Y; Zhang H; Zhao W; Chen B; Wang L; Yang Q
    J Cell Physiol; 2019 Aug; 234(8):13303-13317. PubMed ID: 30618083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MDM4 is a rational target for treating breast cancers with mutant p53.
    Miranda PJ; Buckley D; Raghu D; Pang JB; Takano EA; Vijayakumaran R; Teunisse AF; Posner A; Procter T; Herold MJ; Gamell C; Marine JC; Fox SB; Jochemsen A; Haupt S; Haupt Y
    J Pathol; 2017 Apr; 241(5):661-670. PubMed ID: 28097652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MYC-driven U2SURP regulates alternative splicing of SAT1 to promote triple-negative breast cancer progression.
    Deng L; Liao L; Zhang YL; Hu SY; Yang SY; Ma XY; Huang MY; Zhang FL; Li DQ
    Cancer Lett; 2023 Apr; 560():216124. PubMed ID: 36907504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A defective splicing machinery promotes senescence through MDM4 alternative splicing.
    Deschênes M; Durand M; Olivier MA; Pellerin-Viger A; Rodier F; Chabot B
    Aging Cell; 2024 Nov; 23(11):e14301. PubMed ID: 39118304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
    Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
    Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells.
    Gao C; Xiao G; Piersigilli A; Gou J; Ogunwobi O; Bargonetti J
    Breast Cancer Res; 2019 Jan; 21(1):5. PubMed ID: 30642351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LncRNA SNHG6/miR-125b-5p/BMPR1B Axis: A New Therapeutic Target for Triple-Negative Breast Cancer.
    Lv Y; Lv X; Yang H; Qi X; Wang X; Li C; Shang X; Guo H; Zhang J; Zhang Y
    Front Oncol; 2021; 11():678474. PubMed ID: 34026654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.